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With an increasing number of antimicrobial stewardship–related articles published each year, attempting to stay current is challenging. The Southeastern Research Group Endeavor (SERGE-45) identified antimicrobial stewardship–related peer-reviewed literature that detailed an actionable intervention for 2018. The top 13 publications were selected using a modified Delphi technique.
These manuscripts were reviewed to highlight the actionable intervention used by antimicrobial stewardship programs to provide
key stewardship literature for teaching and training as well as to identify potential intervention opportunities within one’s institution.
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Antimicrobial stewardship has become a common term in acute
care facilities, sparking significant interest among physicians,
pharmacists, and other health care professionals. Antimicrobial
stewardship program (ASP) foundations, including leadership
by infectious diseases (ID) pharmacists and physicians, have
long been established and directed by clinical practice guidelines and regulatory bodies [1–3]. The focus of antimicrobial
stewardship activities continues to move beyond the walls of
inpatient institutions. Certificate programs targeting ID physicians and clinicians working in ambulatory or long-term care
stewardship are now being offered [4–8]. In addition, formal
recommendations and guidance for outpatient and nursing
home ASP activities from the Centers for Disease Control and
Prevention (CDC) and regulatory agencies are available [9–11].
In January 2020, new Joint Commission (TJC) standards for ambulatory care facilities that routinely prescribe antibiotics will
go into effect [12]. Many questions on the optimal execution
of antimicrobial stewardship activities still remain. Given the
variability in institutional settings, local epidemiologic patterns,
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patient mix, and available resources, continued research on successful and optimal ASP interventions is needed [13].
The most successful work in antimicrobial stewardship
has been the result of strong interprofessional collaborations,
with research and scholarship being no exception. Members
of the Southeastern Research Group Endeavor (SERGE-45),
an interprofessional research network primarily composed of
expert pharmacist stewards in the Southeastern United States,
systematically compiled the top peer-reviewed publications
from 2018 involving an ASP intervention. Table 1 provides a
brief overview of the 13 selected articles (aka “Baker’s Dozen”),
which are detailed herein [14–26]. Annual reviews using similar criteria have been previously published since 2016 [27, 28].
METHODS

Using a modified Delphi technique (detailed previously), members of the SERGE-45 network identified antimicrobial stewardship publications from 2018 considered to be significant
using the following inclusion criteria: (1) published in 2018,
including electronic, “early-release” publications, and (2) must
include an actionable intervention [29]. An actionable intervention was defined as a stewardship strategy that was implemented
in practice and resulted in measurable outcomes. Clinical practice guidelines, official statements, review articles, and articles
without an actionable intervention were excluded.
A PubMed search using “antimicrobial stewardship” for 2018
revealed 916 potential publications. EBC and PBB screened
abstracts to ensure that all relevant articles were considered.
In addition, a total of 61 publications were also submitted by
authors for potential inclusion, and comments were provided
electronically to E.B.C., C.M.B., and P.B.B. A total of 117 articles
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Table 1.

Summary of Included Studies

Study Citation Study Design

Intervention Summary

Yadav et al.
2018 [14]

Single-center, quasiInstitutional EP for duration of antiexperimental study
microbial therapy developed and
of incorporation of
approved by hospital committees.
institutional EP for
EP reinforced on ASP rounds. Preexduration of therapy
isting ASP rounds included prospecinto preexisting ASP
tive audit and feedback, restriction
rounds
program, and de-escalation rounds.

Thom et al.
2019 [15]

Multicenter, quasiProvider-driven ATOs were impleexperimental, pre- and mented across 11 units located in 6
postintervention study hospitals. Providers were prompted
to complete paper ATO tool on antibiotic days 3–5 without study or stewardship input.

Foolad et al.
2018 [16]

Multicenter, quasiexperimental study

Musgrove
et al. 2018
[17]

1) Update and dissemination of
institution-specific CAP guidelines
via pocket cards and hospital intranet
sites.
2) Multiple educational sessions to
prescribers and pharmacists regarding appropriate management of
CAP, focusing on DOT, updates to the
institution-specific guidelines, and
the stewardship initiative.
3) Targeted prospective audit with feedback and intervention by ID pharmacists Monday–Friday.
Multicenter, single pre- Clinical microbiology laboratory
and postintervention,
changed wording in reports on nonquasi-experimental
pathogen-containing respiratory
study
cultures to emphasize no Staphylococcus aureus, MRSA, or Pseudomonas aeruginosa.

GarcíaRodríguez
et al. 2019
[18]

Single-center, quasiA multidisciplinary antimicrobial stewexperimental, pre- and ardship team was implemented with
postintervention study prospective follow-up of meropenem
use. An ID physician reviewed the
EMR for each case and provided antibiotic treatment recommendations
to the prescribers, with adherence to
or rejection of the recommendations
from the ID physician assessed at
24–48 hours postrecommendation.
Kulwicki et al. Retrospective, single- Addition of an emergency medicine
2019 [19]
center cohort analysis pharmacist into the ED to provide antimicrobial stewardship.
Adherence to empiric treatment
recommendations for CAP and
community-acquired IAIs was examined pre-EMP and post-EMP. A secondary analysis was undertaken to
examine adherence to these same
guidelines in the early phases of
implementation of an ASP compared
with the established program.
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Primary and Key Secondary Outcomes
Primary outcomes: mean antimicrobial DOTs administered inpatient and
prescribed outpatient for patients discharged with ICD-10 codes for UTI,
SSTI, PNA, VAP in 12 months before and 12 months after implementation
of EP
• Change in mean DOTs: UTI, –1.4 (–2.3 to –0.6; P = .001); SSTI, –2.2 (–3.3
to –1.0; P < .001); PNA, –2.0 (–3.2 to –0.9; P = .001); VAP, –9.6 (–16.0 to
–3.3; P = .003)
Secondary outcomes: total antibiotic exposure (sum of total milligrams of
antibiotics administered inpatient plus prescribed outpatient)
• Change in antibiotic exposure: UTI, –3718 (–5185 to –2252; P < .001);
SSTI, –5404 (–8227 to –2582; P < .001); PNA, –9430 (–12 028 to –6833;
P < .001); VAP, –34 246 (–57 507 to –10 986; P = .004)
No difference between hospital DOT per admission or total DOT per admission before or after controlling for study unit and season
• Average hospital DOT 12.7 vs 12.2 and total DOT 18.9 vs 18.2
• Multivariable analysis showed no association between intervention and
number of times regimen was modified or discontinued on antibiotic
days 3–5 (OR, 1.0; 95% CI, 0.85–1.19)
• Multivariable analysis showed that the ATO was inversely associated with
receipt of inappropriate antibiotics on antibiotic days 3–5 (OR, 0.58; 95%
CI, 0.48–0.69), as was having undergone a surgical procedure (OR, 0.70;
95% CI, 0.54–0.90)
Decrease in median antibiotic DOT
• Historical 9 (IQR, 7–10) days vs intervention 6 (IQR, 5–7) days; P < .001
Improvement in guideline-concordant therapy
• Historical 5.6 % vs intervention 42%; P < .001
Decrease in median excess antibiotic days
• Historical 3 (IQR 2–5) days vs intervention 1 (IQR 0–2) days; P < .001
No significant difference in clinical outcomes 30 days postdischarge, No.
(%)
• CDI: historical 0 (0) vs intervention 0 (0); P = not reported
• Re-presented to emergency center or clinic with pneumonia: historical 20
(6.8) vs intervention 13 (4.4); P = .22
• Readmission with pneumonia: historical 21 (7.1) vs intervention 11 (3.8);
P = .075
• Mortality: historical 7 (2.3) vs intervention 3 (1); P = .233
Primary outcome
• De-escalation: 39% vs 73%; P < .001
Secondary outcomes
• Discontinuation of anti-MRSA therapy: 37% vs 71%; P < .001
• Discontinuation of antipseudomonal therapy: 32% vs 70%; P < .001
• Acute kidney injury: 31% vs 14%; P = .003
• In-hospital, all-cause mortality: 30% vs 18%; P = .52
Improved rates in appropriate justification of meropenem use
• Pre-intervention (2014) 47.3% vs postintervention (2017) 76.8%; P = .001
• Reduction in meropenem consumption (DDD/100 OBDs)
• During 2015–2017, meropenem consumption decreased compared with
2012–2014 (RR, 0.67; 95% CI, 0.58–0.77; P < .001)

Significant difference in total appropriate empiric antibiotic selection with
the EMP vs without the EMP
• 78% vs 61%; P = .001
Significant difference in CAP treatment with the EMP vs without the EMP
• 95% vs 79%; P = .005
Significant difference in community-acquired IAIs treatment with the EMP
vs without the EMP
• 62% vs 44%; P = .025
Significant difference in guideline-directed antibiotic prescribing in the established ASP period compared with the pre-ASP period
• 82.5% vs 60%; P < .001

Table 1.

Continued

Study Citation Study Design
Sacco et al.
2019 [20]

Intervention Summary

Single-center, quasiFollowing development of a validated
experimental pre- and risk stratification algorithm to guide
postintervention study testing and antibiotic use in patients
with penicillin allergy. Health care
professionals were educated on its
use. The algorithm was intended to
guide patient assessment and antibiotic selection. Data were assessed
pre– and post–educational initiative.

Primary and Key Secondary Outcomes
Antibiotic use
• Cephalosporins +121.2%; P = .03
• Penicillins +256%; P = .04
• Vancomycin –67.2%; P = .04
• Fluoroquinolones –33.3%; P = .31
• Carbapenems –81.9%; P = .08
• Aztreonam –73.8%; P = .18
EMR documentation of type of adverse reaction to penicillin in the admission note
• Pre 4.8% vs education 64.9%; P < .001
Use of the test-dose procedure
• 8/27 patients
Occurrence of adverse drug reactions
• None
Length of hospital stay
• Pre 2.33 days vs education 2.07 days

Lee et al. 2018 Retrospective,
[21]
single-center quasiexperimental cohort
analysis

A fluoroquinolone restriction policy was
implemented in 2005. Fluoroquinolone susceptibility was analyzed in
a pre-implementation period (1998–
2004) and a postimplementation
period (2006–2016). Five Gram-negative organisms were included in the
analysis: Escherichia coli, Klebsiella
pneumoniae, Enterobacter cloacae,
P. aeruginosa, and Acinetobacter
species.

Fluoroquinolone use decreased from 173 DOT in the pre-implementation
period to <60 DOT in the postimplementation period
Fluoroquinolone susceptibility increased for:
• Acinetobacter species (RR, 1.038; 95% CI, 1.005–1.072)
• E. cloacae (RR, 1.028; 95% CI, 1.013–1.044)
• P. aeruginosa (RR, 1.013; 95% CI, 1.006–1.020)
Susceptibility did not change significantly for K. pneumoniae (RR, 1.002;
95% CI, 0.996–1.008)
E. coli susceptibility continued to decline postimplementation (RR, 0.981;
95% CI, 0.975–0.987)

Keller et al.
2018 [22]

To reduce the ordering of urinalyses
and urine cultures in patients without
symptoms of a UTI, a series of interventions including the distribution of
educational materials and implementation of CDS alerts in the EMR was
implemented. CDS alerts were placed
on all orders for urinalyses, urine
cultures, and for antibiotics commonly
used for treating UTIs (nitrofurantoin, trimethoprim-sulfamethoxazole,
ciprofloxacin, cefazolin, cephalexin,
and ceftriaxone).

Primary outcome: Urinalysis orders did not significantly decrease
• –10.2%; P = .24
Secondary outcome: Orders for urine cultures did significantly decrease
• –6.3%; P < .001
Other results
• Decrease in simultaneously ordering urinalyses and urine cultures
(–5.8%; P < .001)
• Decrease in urinalysis orders followed by antibiotic orders within 1–24
hours (–0.56%; P = .021)
• Decrease in urine culture results followed by an antibiotic order within 24
hours (–0.24%; P = .036)

Lee et al. 2018 Prospective, multicenter 15-minute education session to clinical
[23]
pre/post chart audit
staff focusing on the appropriate
management of UTI and ASB, complimented by awareness posters and
pocket cards summarizing UTI diagnostic criteria.

Reduction in antibiotic prescriptions for ASB
• Pre-intervention 45 of 50 (90%) vs postintervention 22 of 35 (63%);
P = .003
Increase in proportion of residents presenting with localizing UTI symptoms
• Pre-intervention 21 of 62 (34%) vs postintervention 22 of 50 (44%);
P = .273
Reduction in health care costs
• 64% reduction for pharmacy
• 30% reduction for laboratory

Porter et al.
2018 [24]

Retrospective, singlecenter, before-andafter study

Significant decrease in time to change in optimal therapy (50 vs 160 minutes;
P = .0081)
• Significant increase in percent changed to optimal therapy (41.4% vs
15.6%; P = .013)
• Nonsignificant change in percent changed to effective therapy (17.2% vs
24.4%; P = .462)
• Multivariate regression analysis showed that the intervention group was
significantly less likely to have greater time-to-change value and more
likely to be changed to optimal therapy (P < .01 for both)

Menichetti
et al. 2018
[25]

Retrospective cohort
Restricted use of voriconazole,
comparing those who posaconazole, caspofungin,
received ID consult
anidulafungin, micafungin, liposomal
plus intervention vs
amphotericin B, and lipid complex
intervention alone
amphotericin B to ID, intensive care,
and hematology, plus ID consultation.

Single-center, prospective time series
analysis

Conventional microbiology communication vs mRDT plus pharmacist-driven
reporting protocol for positive blood
cultures.

Primary outcomes
• In-hospital, 30-day mortality 20% with ID consult vs 37% without;
P = .011
Secondary outcomes
• Antibiotic consumption (DDD/100 bed-days): increases in fluconazole (3.1
to 4.3), echinocandins (0.22 to 0.35); decreases in voriconazole (0.25 to
0.18), and amphotericin (0.06 to 0.04)
• Antibiotic cost: increased by €207 000 during study period
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Table 1.

Continued

Study Citation Study Design
Claeys et al.
2018 [26]

Intervention Summary

Retrospective, single- Validation of a theoretical Verigene
center, observational
GNB treatment algorithm based on
study
institutional antibiogram data, evidence-based management, and ASP
practice.

Primary and Key Secondary Outcomes
Significant theoretical decrease in cases receiving appropriate antibiotic
therapy vs standard care (88.4% vs 78.1%; P = .014)
• Strong level of agreement between reviewers regarding algorithm recommendations (ĸ = .855)
• 14.4% appropriate de-escalation and 5.3% appropriate escalation
• 4.8% inappropriate de-escalation and 16% unnecessary escalation

Abbreviations: ASB, asymptomatic bacteriuria; ASP, antimicrobial stewardship program; ATO, antibiotic time-out; CAP, community-acquired pneumonia; CDI, Clostridioides difficile infection;
CDS, clinical decision support; CI, confidence interval; DDD, defined daily dose; DOT, days of therapy; ED, emergency department; EMP, emergency medicine pharmacist; EMR, electronic
medical record; EP, expected practice; GNB, Gram-negative bacteremia; IAI, intra-abdominal infection; ICD-10, International Classification of Diseases, Tenth Revision; ID, infectious diseases;
IQR, interquartile range; mRDT, molecular rapid diagnostic technology; MRSA, methicillin-resistant Staphylococcus aureus; OBD, occupied bed-days; OR, odds ratio; PNA, pneumonia; RR,
rate ratio; SSTI, skin and soft tissue infection; UTI, urinary tract infection; VAP, ventilator-associated pneumonia.

were distributed to the SERGE-45 network for ranking using
SurveyMonkey based on contribution and/or application to
ASP [30]. A teleconference among E.B.C., C.M.B., and P.B.B. reviewed the final ranking and established final consensus on
the top 13 articles based on number of votes received for each
article; all articles are described herein. Figure 1 depicts the
flowchart of database and article selection, and Table 1 is a summary of the selected articles.
RESULTS
Expected Practice and Duration of Therapy

Yadav and colleagues sought to determine the impact of an institutional “expected practice” (EP) for antimicrobial duration of
therapy on total days of therapy (DOT) administered inpatient
and prescribed at discharge for common infections at a large

academic medical center in Los Angeles, California [14]. The EP
document, developed by a interdisciplinary group, listed many
common infections seen in the inpatient and outpatient settings
and referenced shorter courses of therapy with supporting evidence. The EP was endorsed by the Pharmacy & Therapeutics
Committee and Medical Executive Committee. Providers were
asked to explicitly justify longer antimicrobial durations in the
medical record when deemed necessary for optimal patient care.
Implementation included a memo to clinicians and incorporation of EP into ASP rounds. Total DOTs and total antimicrobial
exposure (defined as total mg of antibiotic administered + antibiotic prescribed at discharge) were compared among patients
discharged from the facility in the 12 months before and after implementation of the EP, modeled as a function of the ASP. Patients
were included if International Classification of Diseases, Tenth
Revision (ICD-10), codes corresponding to targeted infectious

Articles retrieved from a PubMed
search using the term
“antimicrobial stewardship”
limited to 2018 publication year
N = 916

Articles that met the inclusion criteria of
actionable antimicrobial stewardship intervention
and distributed for ranking
N = 117

Top ranked articles by memebers of SERGE-45
selected for review
N = 13

Figure 1.

Strategy for identification of top antimicrobial stewardship publications.
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Articles on antimicrobial
stewardship submitted by
members of SERGE-45
N = 61

processes were within the top 20 discharge diagnoses. Covariates
in the model included age, gender, insurance status, in-hospital
and expected mortality, and severity of illness. Significant decreases were observed in average DOT and antimicrobial exposure for all infection types. Mortality was assessed as a measure of
safety for shorter courses of therapy and was similar across both
time periods for each infection type. Use of the procalcitonin
assay, which was implemented at the same time as the EP, was associated with longer durations of therapy. The authors attributed
this to confounding by indication, as clinicians likely ordered
procalcitonin for cases of greater complexity.
ASPs may consider EP an effective way to translate shorter
durations of therapy into new institutional standards of care.
Antibiotic Time-outs and Duration of Therapy

The CDC and TJC recommend the use of interventions such
as antibiotic time-outs (ATOs) or prospective audit and feedback (PAF) to improve antibiotic prescribing [3, 11]. ATOs
may occur as part of standard practice without ASP involvement, prompting providers to have a structured conversations regarding the appropriateness of antibiotic regimens and
durations.
Thom and colleagues performed a quasi-experimental study
pre- and postimplementation of an ATO across 11 units (including adult and pediatric general and intensive care wards) located in 6 different hospitals in Maryland to measure the impact
of a provider-driven ATO [15]. Pre-intervention data were collected during a 6-month baseline period, and postintervention
data were collected for 9 months after implementation of the
paper ATO tool that prompted care teams on antibiotic days 3–5
without input from the study or stewardship team. Primary outcomes were hospital antibiotic DOT per patient admission and
total antibiotic DOT per patient admission, including antibiotic
prescriptions at discharge. Secondary outcomes included antibiotic appropriateness and proportion of cases in which there
was a modification or discontinuation of the regimen within
3–5 calendar days of onset. There was no difference between
hospital DOT per admission or total DOT per admission in the
pre- vs postimplementation groups, before and after controlling
for unit and seasonal differences. Multivariable analysis showed
no association between ATO intervention and number of times
antibiotic regimens were modified or discontinued on days 3–5.
The findings of this study contribute to growing evidence
supporting the impact of ASP input on improving antimicrobial utilization and overall patient outcomes. Further studies
are needed to investigate the impact of additional adjunctive
methods with ASP feedback on antibiotic use.
Optimizing the Treatment of Community-Acquired Pneumonia

The 2007 Infectious Diseaes Society of America (IDSA)/
American Thoracic Society (ATS) guidelines for communityacquired pneumonia (CAP) recommend that patients be

treated for a minimum of 5 days, afebrile for 48–72 hours,
and have no more than 1 CAP-associated sign of clinical instability before discontinuation of therapy [31]. Despite these
recommendations, patients continue to receive longer courses
of therapy, increasing the risk of adverse events and antimicrobial resistance.
Foolad and colleagues conducted a multicenter, pre–post
quasi-experimental study assessing the impact of a multifaceted prospective stewardship intervention on antimicrobial
DOT and clinical outcomes in patients admitted with CAP
to the medicine service at 3 large academic medical centers
in Ann Arbor, Michigan, Milwaukee, Wisconsin, and New
Orleans, Louisiana [16]. Interventions included (1) dissemination of institution-specific CAP guidelines and pocket cards,
(2) educational sessions to prescribers and pharmacists on the
appropriate management of CAP, focusing on DOT, and (3)
targeted PAF and intervention by ID pharmacists Monday–
Friday. Notably, patients admitted to the ICU were excluded.
The primary objective was CAP antimicrobial DOT pre- and
postintervention. Secondary clinical outcomes evaluated included mortality, readmission or presentation to a health care
facility for pneumonia, and incidence of Clostridioides difficile
infection, all at 30 days postdischarge. Six hundred patients were
included in the study, 307 in the historical group and 293 in the
intervention group. Decreases in median antibiotic DOT and
improvement in guideline-concordant therapy were demonstrated postintervention. There were no significant differences
in secondary clinical outcomes within 30 days of discharge.
The authors note that this was the largest study to date assessing the impact of ASP interventions on antibiotic DOT and
clinical outcomes in patients with CAP. It was conducted at 3
large academic institutions and required dedicated ASP pharmacist time and resources to perform PAF, which may limit
generalizability. It is also difficult to assess which intervention
had the greatest impact, as they were implemented concurrently, and the number of interventions performed by the ASP
pharmacists was not reported.
Microbiology Reports and Antibiotic Prescribing for Pneumonia

Antimicrobial prescribing patterns are directly influenced by
clinicians’ interpretation of microbiology results and reports
[32]. Musgrove and colleagues conducted a quasi-experimental
study to compare de-escalation rates before and after changing
respiratory culture reports across a 4-hospital health system
in Detroit, Michigan [17]. The intervention, in combination
with previously established antimicrobial stewardship practices
(eg, syndrome-specific treatment guidelines, PAF), modified
wording on non-pathogen-containing respiratory cultures to
specifically note absence of Staphylococcus aureus, methicillinresistant S. aureus (MRSA), or Pseudomonas aeruginosa. In addition, in-person education was provided to intensive care unit
providers and pharmacists, which was supplemented by a 1-page
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educational handout. One hundred five patients receiving inpatient treatment with anti-MRSA (vancomycin or linezolid)
and antipseudomonal (cefepime, piperacillin/tazobactam,
meropenem, or aztreonam) therapy for respiratory infections
were included in both the 6-month pre- and postintervention
groups. De-escalation and discontinuation of unnecessary antiMRSA and antipseudomonal therapy occurred significantly
more often in the postintervention group, resulting in an average decrease of 2 DOTs. After adjusting for disease severity,
the revised wording on respiratory cultures was associated with
5.5-fold increased odds of de-escalation. Fewer patients in the
postintervention group experienced acute kidney injury, but no
difference was observed in intensive care unit or hospital length
of stay (LOS), or in-hospital, all-cause-mortality.
This study reinforces the importance of microbiology reports
in achieving ASP goals. In addition, the results of this study
demonstrate that simple ASP interventions can result in significant improvements in antimicrobial prescribing.
Optimizing the Use of Meropenem

García-Rodríguez and colleagues performed a quasiexperimental pre/postintervention study to evaluate the impact
of meropenem ASP recommendations on rates of appropriate
justification of treatment, antibiotic consumption measures,
infection-related and all-cause mortality, and incidence of
multidrug-resistant hospital-acquired bloodstream infections
[18]. Additional clinical and economical comparisons were described between the groups of patients with and without acceptance of ASP recommendations when meropenem did not fulfill
justification criteria.
This study describes a resource-limited approach by a multidisciplinary team to improve meropenem utilization at a single
350-bed teaching hospital in Spain from 2015 to 2017. Local
guidelines for empiric antibiotic treatment were developed and
made accessible on every hospital desktop computer. In addition, active surveillance was performed 6 hours weekly by an ID
physician who reviewed each case and provided recommendations to prescribers in 1 of the following ways: face to face, telephone, or through the electronic medical record (EMR). During
the last 4 months of 2014, patient cases with meropenem were
reviewed retrospectively as the pre-intervention study group
for comparison. Overall, in the pre-intervention period, 47.3%
of the 150 patients receiving meropenem were considered justified based on study criteria for appropriate treatment, which
included severe sepsis, history of extended spectrum betalactamase (ESBL) colonization, or hospital-acquired infection
in which broad-spectrum antibiotics were necessary. There
were 852 patients who received meropenem treatment during
the intervention period, with 61% of cases considered justified
or appropriate. Of the 330 cases that were not considered justified, the prescribers accepted 82% of the ID physician recommendations. Acceptance of intervention was associated with
6 • ofid • Chahine et al

shorter duration of antibiotic treatment and inpatient days. The
study further compared patients with and without acceptance
of ASP recommendations and found that pulmonary and abdominal infections were associated with lower acceptance rates.
Overall, there was a 33% decrease in meropenem consumption
when comparing the pre-intervention years (2012–2014) with
the intervention years (2015–2017).
The strength of this study is that it can be replicated in settings where targeting a specific antibiotic is needed and an ID
physician is available for intervention. Despite these results, it
remains important to consider syndrome-specific interventions
that may result in advantageous declines in antibiotic utilization and avoid compensatory increases in other broad-spectrum antibiotics.
Emergency Medicine Pharmacist and Antibiotic Prescribing for CAP and
Intra-abdominal Infections

In the United States, approximately 16% of all patients who visit
the emergency department (ED) each year receive an antibiotic,
but many are either inappropriate or unnecessary [33, 34]. ASPs
can help improve antibiotic prescribing practices, including in
the ED, and pharmacists play an important role in the provision
of ASPs [35].
Kulwicki and colleagues conducted a retrospective cohort
analysis to determine the effect of an emergency medicine pharmacist (EMP) on the selection of appropriate empiric antibiotics
for the treatment of CAP and community-acquired intraabdominal infections (IAIs) in the ED, compared with having
no EMP, in Grand Rapids, Michigan [19]. Determination of appropriate antibiotics was based on following institutional protocols derived from IDSA guidelines, in conjunction with local
antimicrobial resistance patterns. A secondary objective was to
examine empiric antibiotic prescribing for these 2 disease states
in the ED during a period of early ASP (2014) compared with
an established ASP (2016). Three-hundred twenty patients were
included (185 in the EMP group and 135 in the no-EMP group).
Appropriate empiric prescribing occurred more often in the
EMP group compared with the no-EMP group. Treatment of
both CAP and community-acquired IAIs was more likely to be
appropriate in the EMP group compared with the non-EMP
group. Further, guideline-directed antibiotic prescribing significantly improved from the early ASP period to the established
ASP period.
Overall, the results of this study demonstrate the positive impact of having an EMP as a steward extender for ASPs.
Use of an Inpatient Penicillin Allergy Assessment Protocol

Allergy to penicillin is one of the most frequently reported and
documented allergies. Over 30 million patients have reported
an allergy to penicillin, and as many as 90% of these allergies are inaccurate [36]. Carrying this label has an impact on
ASP, as it leads to increased prescribing of broad-spectrum or

second-line agents, as well as increased LOS and overall costs
[36]. One intervention used to assess patients with a history of
IgE-mediated allergy is penicillin skin testing (PST); however,
logistics and access to PST can be limited [37].
Sacco and colleagues performed a single-center, quasiexperimental pre- and postintervention study in Jacksonville,
Florida, to assess the effects on antibiotic prescribing after education and implementation of a validated algorithm that categorizes patients based on risk stratification [20]. Providers
were educated by an allergist on penicillin allergies and given a
standardized algorithm to help with taking a proper history and
antibiotic selection. In the pre- and postintervention cohort of
patients admitted to the general medicine ward with a reported
penicillin allergy, there were 42 and 57 patients, respectively.
Documentation of allergy reaction history on admission improved from 4.8% pre-intervention to 64.9% postintervention
(P < .001). Penicillin and cephalosporin usage increased by
256% and 121%, respectively, whereas vancomycin, fluoroquinolone, carbapenem, and aztreonam usage decreased.
Although only a single center with limited sample size, this
study demonstrated that education and standardization of prescribing can affect antibiotic selection in patients who present
with a penicillin allergy to facilities with limited resources to
routinely perform PST.
Fluoroquinolone Use and Pre-authorization Policy

Fluoroquinolone use in the United States has steadily increased
in the past decade, with a concomitant increase in resistance,
particularly among Gram-negative organisms [38, 39]. ASPs
can improve fluoroquinolone use and lead to improvements in
susceptibility.
Lee and colleagues conducted a retrospective, quasiexperimental study to examine fluoroquinolone susceptibility before (pre-intervention period 1998–2005) and after
(postintervention period 2006–2016) implementation of a
policy that required ASP approval for empiric fluoroquinolone
use at a large academic medical center in Birmingham, Alabama
[21]. Susceptibility patterns of 5 Gram-negative organisms were
analyzed: Escherichia coli, Klebsiella pneumoniae, Enterobacter
cloacae, P. aeruginosa, and Acinetobacter species. Inpatient
use of fluoroquinolones increased steadily beginning in 1998,
peaking in 2004 with 173 DOT per 1000 patient-days. The
fluoroquinolone prior authorization policy was implemented in
October 2005 and was successful in reducing fluoroquinolone
use. Between 2006 and 2016, fluoroquinolone use was <60 DOT
per 1000 patient-days. In the postintervention period, fluoroquinolone susceptibility significantly increased (P < .0001) for
Acinetobacter species, E. cloacae, and P. aeruginosa. No significant change was noted for K. pneumoniae. The susceptibility
for E. coli continued to decline, albeit not as dramatically as in
the pre-intervention period. Both E. coli and K. pneumoniae
are often community-onset pathogens, and unrestricted

fluoroquinolone use in the community setting would likely contribute to the lack of significant impact on susceptibilities.
One limitation of this study was that the data were from a
single academic center. In addition, a control unit or hospital
could not be used for comparison because the fluoroquinolone
restriction was universally applied. The results of this study
demonstrate the effectiveness of a fluoroquinolone restriction
policy in decreasing overall use and improvement in susceptibility of hospital-acquired Gram-negative organisms.
Asymptomatic Bacteriuria and Clinical Decision Support

Asymptomatic bacteriuria (ASB) is a common medical condition that seldom requires treatment [40]. Obtaining urinalyses
and urine cultures in patients without signs or symptoms of
a urinary tract infection (UTI) can lead to unnecessary antibiotics, which in turn leads to increasing resistance [41, 42].
Keller and colleagues implemented a combination of interventions to reduce urine testing for ASB that included provider
education and clinical decision support (CDS) alerts in the EMR
at a large academic medical center in Baltimore, Maryland [22].
In August 2015, educational materials were placed on hospitalwide screen savers and disseminated through a newsletter email.
The CDS tools included informational messages recommending
not to test for UTIs in patients without symptoms and recommending against treating ASB. These messages appeared on all
EMR orders for urinalysis, urine culture, and for antibiotics
commonly used for treating UTIs. The authors performed a
prospective time series analysis utilizing a pre-intervention
phase (September 2014–June 2015) and a postintervention
phase (September 2015–June 2016). Orders for urinalyses did
not decrease significantly but orders for urine cultures significantly decreased. Additionally, in the postintervention phase,
there was a decrease in simultaneously ordering urinalyses and
urine cultures (–5.8%), a decrease in urinalysis orders followed
by antibiotic orders within 1–24 hours (–0.56%), and a decrease
in urine culture results followed by an antibiotic order within
24 hours (–0.24%).
This study has a number of limitations, including short duration (<1 year) and a single center, and appropriateness of each
antibiotic-based documentation of symptoms was not assessed.
Overall, this study demonstrated that the use of educational
materials and CDS may reduce the number of urine cultures
ordered and antibiotics prescribed for the treatment of ASB.
Asymptomatic Bacteriuria and Antibiotic Use in the Long-term Care
Setting

Unnecessary antimicrobial use in long-term care (LTC) residents related to ASB has been identified as a major area of opportunity for improvement and has led to efforts such as the
“Symptom-Free Pee, Let It Be” campaign [43]. The best approach to increasing appropriate ASB management in the LTC
setting is not known, and great interest exists in identifying
Top Antimicrobial Stewardship Publications • ofid • 7

viable methods for tackling the problem, particularly in
resource-limited organizations.
Lee and colleagues undertook an evaluation of an educational intervention related to ASB in patients at 7 LTC facilities
in Regina, Saskatchewan, Canada, with the primary outcome
of percentage of residents who received inappropriate antibiotic
treatment for ASB [23]. There was a pre-assessment period and
a postassessment period of 5 weeks each, and the intervention
took place during the 2 weeks in between. The intervention was
designed to include feedback and monitoring, shaping knowledge, natural consequences, and comparison of behavior. The
intervention included educational sessions that incorporated
information on ASB treatment guidelines, local findings from
the pre-intervention audit, and diagnostic criteria for UTIs.
Educational posters were displayed after the 15-minute sessions, and pocket cards were distributed. Educational efforts
were focused toward clinical staff, which was primarily made up
of nursing staff. Intervention demonstrated a decrease in ABS
antibiotic prescribing from 90% to 63%
One important limitation to this study is that only 15% of the
clinical staff were present for an educational session and physicians were not included. Additionally, the study period was relatively short, with long-term impact unknown. However, this
resource- and time-limited effort was effective in improving
ASB management at 7 different LTC facilities.
Multiplex Polymerase Chain Reaction Blood Culture Results vs
Conventional Microbiology Methods

Rapid identification of organisms and timely optimization of
therapy are important to limit morbidity and mortality, decrease
use of broad-spectrum agents, and improve clinical response
[44–47]. With recent advancements in molecular rapid diagnostic
technology (mRDT), organisms can be identified faster than the
conventional 48–72 hours. Pharmacists are optimally placed to
aid in correct interpretation and application of these results.
Porter and colleagues performed a single-center, retrospective, before-and-after study comparing time with change in
antimicrobial therapy between a conventional microbiology
protocol (December 2014–November 2015) and multiplex
polymerase chain reaction with pharmacist-driven reporting
protocol (April 2016–March 2017) at a community hospital in
Savannah, Georgia [24]. Conventional protocol included results being communicated to a nurse, who would then notify
the provider. The intervention group consisted of pharmacists
utilizing a protocol developed and approved by the ASP subcommittee to notify the team, make recommendations, and
enter accepted orders into the EMR. The primary outcome of
time to change in antimicrobial therapy was measured from
time of call with results to time of antimicrobial change, with
only changes within 24 hours and initial calls being included.
Secondary outcomes further divided results by time to change
from suboptimal to optimal therapy or from ineffective to
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effective therapy. Change to optimal therapy included escalation to vancomycin for MRSA and discontinuation of vancomycin when clinically unnecessary. Patients in the intervention
group (77/118) had decreased median time-to-change values
for effective therapy (50 vs 160 minutes; P = .0081), and a higher
percentage were changed to optimal therapy (41.4% vs 15.6%;
P = .013). Additionally, there was a significant decrease in vancomycin utilization for coagulase-negative Staphylococcus spp.
in the intervention group (69.3% vs 10%; P < .01).
Lack of improvement in clinical outcomes with mRDT
without ASP intervention has been previously established. This
study provides evidence for clinical benefits with mRDT and
pharmacist involvement in resource-limited institutions, enabling front-line pharmacists to provide direct recommendations,
with additional backup by ASP pharmacists through approved
protocols. Additionally, analysis of immediate changes only may
more closely represent the impact of ASP and the protocol.
ASP With or Without ID Consults and Candidemia

With the persistently high rates of associated mortality, programs
have been targeting candidemia for antifungal stewardship interventions [48–51]. Menichetti and colleagues conducted a singlecenter retrospective study evaluating patients receiving an ID
consultation in combination with an antifungal stewardship program vs those who did not at a large academic medical center in
Italy [25]. The intervention consisted of antifungal restriction for
most agents outside of fluconazole, requiring authorization via ID
consult. ID consults were at the discretion of the primary provider
and were completed within 24–36 hours of the request by 2 senior
ID physicians. Education regarding awareness and appropriate
treatment of candidemia based on published guidelines was additionally provided during the study period. The primary outcome
was impact of the antifungal stewardship program with or without
ID consultation on in-hospital 30-day mortality associated with
candidemia. Secondary outcomes included mortality risk factors,
antifungal consumption, and cost. From 2012 to 2014, 276 patients were included (76 with ID consult, 200 without). In-hospital
30-day mortality was 20% for patients with an ID consult and 37%
for those without (P = .011). Of note, 26% of patients in the group
without ID consult received no antifungal treatment. On univariate analysis, age >65 years and admission to an internal medicine ward were associated with higher risk of death, whereas ID
consult, late-onset candidemia, and nonalbicans Candida species
were protective. In multivariate analysis, ID consult, nonalbicans
Candida species, and age remained significant. During the study
period, fluconazole and echinocandin use increased, whereas
voriconazole and amphotericin decreased.
Limitations include the small sample size, retrospective
single-center design, and lack of information on source control. Further study on the impact of antifungal stewardship on
patient outcome metrics would be beneficial in extrapolating
these data to other institutions.

mRDT for Gram-Negative Bacteremia

Timely, appropriate antibiotic therapy is key for improved
morbidity and mortality in Gram-negative bacteremia (GNB).
The Verigene Blood Culture Gram-Negative (BC-GN) rapid
diagnostic test can quickly identify 8 common target organisms and 6 resistance determinants with 97.1% sensitivity and
99.5% specificity [52, 53]. It is important to pair these with ASP
involvement.
In a retrospective, single-center, observational study at a
large academic medical center in Baltimore, Maryland, Claeys
and colleagues developed a GNB treatment algorithm based
on institution-specific antibiogram data and evidence-based
practice [26]. A cutoff value of at least 88% susceptible, based
on the reported susceptibility of piperacillin/tazobactam, was
utilized for Gram-negative organisms without a resistance
mechanism identified by Verigene BC-GN. Empiric therapy
with meropenem was utilized in immunocompromised or critically ill patients where the antibiogram data showed higher
rates of third-generation cephalosporin resistance with E. coli
and Klebsiella spp. ASP pharmacists determined definitions
for standard care (empiric) vs algorithm-based (optimal and
targeted) antibiotic therapy and independently evaluated
the appropriateness of standard care vs theoretical receipt of
algorithm-based therapy. Allergy history or reconciliation was
not considered for this assessment. Out of 144 patients with
Verigene BC-GN target organisms, there was a moderate level
of agreement between the reviewers regarding the appropriateness of standard care antibiotics and a strong level of agreement for algorithm recommendations. In vitro susceptibility
was higher with algorithm-recommended therapy (92.1% vs
77.8%), and significantly more cases would have received appropriate therapy (88.4% vs 78.1%). Although 14.4% of cases
were appropriately de-escalated, 4.8% were inappropriately
de-escalated; related risk factors included polymicrobial GNB,
central line source, Acinetobacter spp., Enterobacter spp., and/or
OXA+ resistance determinants.
The strengths of this study include validation of a GNB treatment algorithm based on institution-specific antibiogram data,
Verigene BC-GN results, and ASP input. This combination
showed the potential for increase in patients receiving timely,
appropriate therapy with theoretical, retrospective validation.
ASPs interested in this implementation strategy must note that
100% adherence to the algorithm may cause unnecessary escalation or inappropriate de-escalation and should customize their
algorithm according to their institutional data and practices.
DISCUSSION

Novel antimicrobial stewardship interventions continue to
move practice and research forward for clinicians and ASP
stakeholders. The scholarship highlighted in this review demonstrates a continued commitment to novel models of stewardship interventions, value assessment of mRDT implementation,

and integration of stewardship into areas outside the traditional
inpatient walls of an academic medical center (eg, community
hospitals, LTC facilities). As the quantity of stewardship publications increases, it is important that the quality and scientific rigor of research increases as well [13]. For many inpatient
institutions, antimicrobial stewardship is not a new concept;
thus scholarship demonstrating sustainability is important.
Clinicians and scholars should ensure that stewardship training
includes skills development on research study design, methods,
and data analysis. Mentoring by and collaboration with established scholars will aid new stewards in executing high-quality
scholarship and promote generalizability of results. Prospective,
interventional stewardship studies conducted across multiple
centers outside the umbrella of a single health system would
provide the quality evidence needed to establish best practices
and efficient models to optimize antimicrobial therapy.
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